Download This Paper
Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.
One-Fourth of COVID-19 Patients Have an Impaired Pulmonary Function after 12 Months of Illness Onset
21 Pages Posted: 24 Feb 2023
More...Abstract
Background: This longitudinal study evaluates the extent of impaired pulmonary function over time after SARS-CoV-2 infection across the full spectrum of COVID-19 severity.
Methods: Pulmonary function was measured by diffusing capacity for carbon monoxide (DLCO) at one, six, and twelve months after illness onset. Additionally, data on sociodemographics, clinical characteristics, symptoms, and health-related quality of life (HRQL) were collected. Pulmonary function and determinants were modelled over time using mixed-effect linear regression. Determinants of pulmonary impairment at 12 months since illness onset were identified using logistic regression.
Findings: Between May 2020 and December 2021, 301 of 349 participants underwent at least one pulmonary function test. After one year of follow-up, 25% of the participants had an impaired pulmonary function which translates in 11%, 22%, and 48% of the participants with mild, moderate and severe/critical COVID-19. Improvement in DLCO among the participants continued over the period across one, six and twelve months. Having more than three comorbidities (p<0·001) and initial severe/critical illness (p<0·001) were associated with slower improvement of pulmonary function over time, adjusted for age and sex. HRQL improved over time and was not different to those without impaired pulmonary function.
Interpretation: The prevalence of impaired pulmonary function after twelve months of follow-up, was still significant among those with initially moderate or severe/critical COVID-19. However, those who continued to have impaired pulmonary function after one year did not have impaired HRQL.
Funding: This work was supported by the Netherlands Organization for Health Research and Development (ZonMw) [10150062010002 to M.D.d.J.] and the Public Health Service of Amsterdam [R&D in 2021 and 2022 to M.P.].
Declaration of Interest: All authors declare no competing interests.
Ethical Approval: Written informed consent was obtained from each study participant. The study design was approved by the local ethics committee of the Amsterdam UMC (Medisch Ethische Toetsingscommissie [METC]; NL73759.018.20).
Keywords: COVID-19, pulmonary function, HRQL, post-acute sequelae, long COVID
Suggested Citation: Suggested Citation